이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Iconovo 관리

관리 기준 확인 2/4

Iconovo's CEO는 Johan Waborg, Jan2020 에 임명되었습니다 의 임기는 4.58 년입니다. 는 SEK 638.86K 가치에 해당하는 회사 주식의 0.47% 직접 소유합니다. 638.86K. 경영진과 이사회의 평균 재임 기간은 각각 3.1 년과 5.6 년입니다.

주요 정보

Johan Waborg

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	4.6yrs
CEO 소유권	0.5%
경영진 평균 재임 기간	3.1yrs
이사회 평균 재임 기간	5.6yrs

최근 관리 업데이트

Recent updates

Iconovo AB (publ)'s (STO:ICO) Intrinsic Value Is Potentially 37% Above Its Share Price

Jun 13

Companies Like Iconovo (STO:ICO) Can Afford To Invest In Growth

Apr 13

When Will Iconovo AB (publ) (STO:ICO) Turn A Profit?

Mar 18

Have Iconovo AB (publ) (STO:ICO) Insiders Been Selling Their Stock?

Feb 20

A Look At Iconovo's (STO:ICO) Share Price Returns

Feb 07

Have Insiders Been Buying Iconovo AB (publ) (STO:ICO) Shares?

Dec 21

CEO

Johan Waborg (47 yo)

4.6yrs

테뉴어

Mr. Johan Wäborg serves as Chief Executive Officer at Iconovo AB (publ) since 2020.

리더십 팀

이름	위치	테뉴어	보상	소유권
Johan Waborg	Chief Executive Officer	4.6yrs	데이터 없음	0.47% SEK 638.9k
Orest Lastow	Co-Founder	4.6yrs	데이터 없음	5.19% SEK 7.1m
Henrik Simonssen	Chief Financial Officer	1.3yrs	데이터 없음	데이터 없음
Mikael Arinder	Vice President of Operations	8.6yrs	데이터 없음	0.11% SEK 154.8k
Josefin Olsen	HR Manager	1.6yrs	데이터 없음	데이터 없음
Carl Forslund	Head of Industrial Design	no data	데이터 없음	데이터 없음
Therese Dahl	Business Controller	1.6yrs	데이터 없음	데이터 없음

3.1yrs

평균 재임 기간

60yo

평균 연령

경험이 풍부한 관리: ICO 의 관리팀은 경험 ( 3.1 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Orest Lastow	Co-Founder	11.6yrs	데이터 없음	5.19% SEK 7.1m
Mats Johansson	Director	11.6yrs	데이터 없음	7.86% SEK 10.8m
Gunnar Gardemyr	Independent Chairman of the Board	4.6yrs	데이터 없음	0.20% SEK 279.5k
Kjell Larsson	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Lennart Holm	Member of Business Advisory Board	no data	데이터 없음	데이터 없음
Rikard Roos	Member of Business Advisory Board	no data	데이터 없음	데이터 없음
Ann Gidner	Independent Director	3.6yrs	데이터 없음	데이터 없음
Berndt Axelsson	Independent Director	11.6yrs	데이터 없음	2.01% SEK 2.8m
Björn Andersson	Member of Business Advisory Board	no data	데이터 없음	데이터 없음
Carl Lindgren	Independent Director	1.3yrs	데이터 없음	0.25% SEK 344.0k
Agneta Walhagen	Independent Director	5.6yrs	데이터 없음	0.028% SEK 38.7k

5.6yrs

평균 재임 기간

63yo

평균 연령

경험이 풍부한 이사회: ICO 의 이사회는 경험(평균 재직 기간 5.6 년)으로 간주됩니다.

Iconovo 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Vice President of Operations recently bought kr80k worth of stock

Independent Director recently bought kr246k worth of stock

Iconovo AB (publ), Annual General Meeting, May 21, 2024

Insufficient new directors

Independent Chairman of the Board recently bought kr190k worth of stock

Iconovo AB (Publ) Announces Appoints Carl Lindgren as Chief Business Development Officer

Recent updates

Second quarter 2024 earnings released: kr0.60 loss per share (vs kr1.32 loss in 2Q 2023)

Now 21% overvalued after recent price rise

Iconovo AB (publ) to Report Q4, 2024 Results on Feb 27, 2025

Vice President of Operations recently bought kr80k worth of stock

Independent Director recently bought kr246k worth of stock

Now 22% overvalued after recent price rise

Iconovo AB (Publ) Files Patent Application for Inhaled GLP-1 Products and Initiates Development of New Obesity Treatments

Consensus revenue estimates increase by 15%, EPS downgraded

New major risk - Shareholder dilution

Iconovo AB (publ) Receives Patent Protection for Icores in China

Iconovo AB (publ), Annual General Meeting, May 21, 2024

First quarter 2024 earnings released: kr0.69 loss per share (vs kr1.35 loss in 1Q 2023)

New major risk - Revenue and earnings growth

Iconovo AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 18.8 million.

Iconovo AB (publ) to Report Q1, 2024 Results on Apr 25, 2024

New major risk - Market cap size

Insufficient new directors

New minor risk - Profitability

New major risk - Market cap size

Independent Chairman of the Board recently bought kr190k worth of stock

Third quarter 2023 earnings released: kr0.97 loss per share (vs kr1.14 loss in 3Q 2022)

Iconovo AB (publ) Completes Enrollment in Phase I Clinical Trial of Inhaled Oxytocin in ICOone

Iconovo AB (publ) Receives US Patent for Ioccap That Strengthens the Offering for More Customer Collaborations

Iconovo AB (Publ) Provides Earnings Guidance for the Years 2024, 2025, 2026 and 2027

New minor risk - Share price stability

New major risk - Financial position

Second quarter 2023 earnings released: kr1.36 loss per share (vs kr1.38 loss in 2Q 2022)

We're A Little Worried About Iconovo's (STO:ICO) Cash Burn Rate

Price target decreased by 27% to kr63.00

Iconovo AB (publ) Strengthens its Customer Offering in the Novel Pharmaceuticals Business Segment

Iconovo AB (Publ) Announces Appoints Carl Lindgren as Chief Business Development Officer

Independent Director recently sold kr98k worth of stock

Independent Director recently sold kr171k worth of stock

Chief Executive Officer recently bought kr61k worth of stock

Independent Chairman of the Board recently bought kr100k worth of stock

Iconovo AB (publ) to Report Fiscal Year 2022 Results on Feb 08, 2023

Insufficient new directors

Iconovo Receives Approval of New European Patent for Its Single-Use Inhaler ICOone®

Iconovo AB (publ) Announces Executive Changes, Effective April 1, 2023

Iconovo's ICOone Inhaler Platform Receives New Patent Approval in the US

Iconovo Announces Appointment of Nomination Committee

Third quarter 2022 earnings released: kr1.14 loss per share (vs kr0.43 loss in 3Q 2021)

Iconovo AB (publ) Conducts a User Study to Assess the Handling of its ICOone Nasal Inhaler

Here's Why We're Watching Iconovo's (STO:ICO) Cash Burn Situation

Second quarter 2022 earnings released: kr1.38 loss per share (vs kr0.85 loss in 2Q 2021)

Iconovo AB (Publ) Announces First Patent Grant in Japan for It's ICOone

Chief Executive Officer recently bought kr69k worth of stock

Director recently bought kr258k worth of stock

Chief Executive Officer recently bought kr104k worth of stock

Price target increased to kr140

Full year 2021 earnings: EPS and revenues miss analyst expectations

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Iconovo AB (publ) Announces Completion of Comparative Clinical Study of Icores Budesonide/Formoterol and Symbicort Turbuhaler

Chief Financial Officer recently bought kr53k worth of stock

Director recently bought kr78k worth of stock

No longer forecast to breakeven

Director recently bought kr109k worth of stock

Chairman of the Board recently bought kr372k worth of stock

Companies Like Iconovo (STO:ICO) Are In A Position To Invest In Growth

Chief Executive Officer recently bought kr151k worth of stock

Third quarter 2021 earnings released

Chairman of the Board recently bought kr248k worth of stock

Insider recently bought kr53k worth of stock

Chairman of the Board recently bought kr421k worth of stock

We're Not Worried About Iconovo's (STO:ICO) Cash Burn

Is Now The Time To Look At Buying Iconovo AB (publ) (STO:ICO)?

Chairman of the Board recently bought kr378k worth of stock

Iconovo AB (publ)'s (STO:ICO) Intrinsic Value Is Potentially 37% Above Its Share Price

Chairman of the Board recently bought kr689k worth of stock